Clinical Trial
doi: 10.1002/mds.20018.
Minocycline in Huntington's disease: a pilot study
Affiliations
- PMID: 15197710
- DOI: 10.1002/mds.20018
Item in Clipboard
Clinical Trial
Minocycline in Huntington's disease: a pilot study
Mov Disord.
2004 Jun.
Abstract
Minocycline is a caspase inhibitor, decreases inducible nitric oxide synthase (iNOS), and has been shown to delay disease progression in the mouse model R6/2 of Huntington's disease (HD). This safety and tolerability study included 30 patients with HD who were given minocycline over a 6-month period and underwent assessments every 2 months with laboratory studies, the Abnormal Involuntary Movements Scale, the Unified Huntington's Disease Rating Scale, and the Mini-Mental State Examination. Minocycline was well tolerated during this study period and no serious adverse events were noted.
Copyright 2004 Movement Disorder Society
Comment in
-
Huntington's disease and minocycline.Mov Disord. 2005 Apr;20(4):510-511. doi: 10.1002/mds.20441. Mov Disord. 2005. PMID: 15806589 No abstract available.
Similar articles
-
Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.Nat Med. 2000 Jul;6(7):797-801. doi: 10.1038/77528. Nat Med. 2000. PMID: 10888929
-
A pilot study using nabilone for symptomatic treatment in Huntington's disease.Mov Disord. 2009 Nov 15;24(15):2254-9. doi: 10.1002/mds.22809. Mov Disord. 2009. PMID: 19845035 Clinical Trial.
-
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.Mov Disord. 2007 Dec;22(16):2359-64. doi: 10.1002/mds.21718. Mov Disord. 2007. PMID: 17894335 Clinical Trial.
-
[Neuropsychological deterioration in Huntington's disease].Rev Neurol. 1997 Aug;25(144):1257-68. Rev Neurol. 1997. PMID: 9340161 Review. Spanish.
-
Clinical potential of minocycline for neurodegenerative disorders.Neurobiol Dis. 2004 Dec;17(3):359-66. doi: 10.1016/j.nbd.2004.07.012. Neurobiol Dis. 2004. PMID: 15571972 Review.
Cited by
-
Oral Minocycline Therapy Improves Symptoms of Myalgic Encephalomyelitis, Especially in the Initial Disease Stage.Intern Med. 2021 Aug 15;60(16):2577-2584. doi: 10.2169/internalmedicine.6082-20. Epub 2021 Apr 26. Intern Med. 2021. PMID: 33896862 Free PMC article.
-
The Role of Microglia and Astrocytes in Huntington's Disease.Front Mol Neurosci. 2019 Oct 25;12:258. doi: 10.3389/fnmol.2019.00258. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31708741 Free PMC article.
-
Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline.PLoS One. 2010 Mar 22;5(3):e9793. doi: 10.1371/journal.pone.0009793. PLoS One. 2010. PMID: 20339553 Free PMC article.
-
Activated Microglia Targeting Dendrimer-Minocycline Conjugate as Therapeutics for Neuroinflammation.Bioconjug Chem. 2017 Nov 15;28(11):2874-2886. doi: 10.1021/acs.bioconjchem.7b00569. Epub 2017 Oct 27. Bioconjug Chem. 2017. PMID: 29028353 Free PMC article.
-
Protective Proteolysis in Huntington's Disease: Unraveling the Role of Post-Translational Myristoylation of Huntingtin in Autophagy.J Huntingtons Dis. 2024;13(3):267-277. doi: 10.3233/JHD-240028. J Huntingtons Dis. 2024. PMID: 38995796 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
